Fact CheckerSign in

NCT07518862Recruiting

Heart Rate VAriability as a MaRker for tItrATing hIgh flOw Nasal Cannula Therapy

Heart Rate Variability as a Marker for Titrating High Flow Nasal Cannula Therapy in Patients With Respiratory Failure

Source: ClinicalTrials.gov · Last updated 18 Jun 2026

Brief summary (registry, in English)

High-flow nasal cannula is a type of non-invasive respiratory support that helps patients breathe more comfortably. Because the flow is high, it can deliver more oxygen to the lungs and make breathing easier by reducing the effort needed to breathe. However, the best strategy to determine the best oxygen flow rate remains uncertain. Reducing flow rates prematurely can increase work of breathing and prolong ICU stay, while unnecessary prolongation can increase costs. Currently, evidence to guide titration is limited. Heart rate variability is the natural variation in the time between each heartbeat. Heart rate variability reflects the level of autonomic nervous system activity in response to stress. The autonomic nervous system is the part of the nervous system that automatically controls how heart rate speeds up and slows down. When heart rate variability is higher, it indicates that the system is able to adjust to changes in the body, including stress. However, when heart rate variability is low, it indicates that the system is constrained and in a state of stress. The VARIATION study is designed to characterize how heart rate variability goal of this observational study is to learn whether heart rate variability can serve as a marker of the appropriateness of high flow nasal cannula flow support during flow titration in patients with respiratory failure. The main question it aims to answer is: Does heart rate variability change before other conventional respiratory signs when there are changes in respiratory function due to inadequate flow rate? Participants already on high flow nasal cannula as part of their regular medical care will: 1. Undergo a stepwise decrease in high flow nasal cannula flow rate. 2. Be recorded continuously with electrocardiogram and electrical impedance tomography.

Status (registry)
Recruiting
Study type
Observational
Enrollment
20 (estimated)
First submitted
1 Apr 2026
Start date
26 May 2026
Primary completion date
30 Nov 2026
Lead sponsor
University Health Network, Toronto
NCT number
NCT07518862

What you commit to

  • Study type: Observational
  • Planned participants: 20
  • From 26 May 2026 to the primary completion date, 30 Nov 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Post-cardiac surgery patients

Other

  • FiO2 ≥ 90%
  • Pacemaker rhythm or presence of atrial fibrillation
  • Contra-indications to electrical impedance tomography (EIT) and/or electrocardiogram (ECG) (active implantable medical device, burns, thoracic wounds limiting electrode placement)
  • Non-English-speaking

Who the study is looking for

  • Age \> 18
  • Currently receiving High-Flow Nasal Cannula Therapy

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Toronto General Hospital
Coordinator of this site? Confirm its status
TorontoCanadaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.